Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $27.77 Average Target Price from Analysts
Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month […]
Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month […]
